Literature DB >> 6796932

Cholesterol, children, and heart disease: an analysis of alternatives.

D M Berwick, S Cretin, E Keeler.   

Abstract

Cost-effectiveness analysis is used to compare proposed cholesterol control programs. The analysis employs estimates of such biologic variables as effect of diet on cholesterol level, stability of level, and change in morbidity with level. Sensitivity analysis identifies the biologic and behavioral uncertainties that most critically affect policy choices. At a discount rate of 5%, a cholesterol-screening program for all 10-year-old children would cost about 10,000 per year of life saved. Rescreening would not improve efficiency. Targeted screening a high-risk children could improve efficiency by 25%, but would benefit only one sixth as many people. Community-wide interventions without screening may be more efficient by a factor of 3. The cost per year of life saved is most affected by the rate of discount and the dollar cost of changing behavior, but is insensitive to stability of cholesterol rank order and to the cost of screening.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6796932

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  10 in total

Review 1.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 2.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 3.  Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.

Authors:  D Thompson; G Oster
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

4.  The reliability of cost-utility estimates in cost-per-QALY league tables .

Authors:  S Petrou; M Malek; P G Davey
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 5.  Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Authors:  P Chrisp; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 6.  Cost effectiveness of coronary heart disease prevention strategies in adults.

Authors:  A D Brown; A M Garber
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

Review 7.  Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.

Authors:  T van der Weijden; J A Knottnerus; A J Ament; H E Stoffers; R P Grol
Journal:  J Epidemiol Community Health       Date:  1998-09       Impact factor: 3.710

8.  Temporal trends in lipid screening and therapy among youth from 2002 to 2012.

Authors:  Justin P Zachariah; Catherine J McNeal; Laurel A Copeland; Ying Fang-Hollingsworth; Eileen M Stock; FangFang Sun; Joon Jin Song; Sean T Gregory; Jeffrey O Tom; Eric A Wright; Jeffrey J VanWormer; Andrea E Cassidy-Bushrow
Journal:  J Clin Lipidol       Date:  2015-07-09       Impact factor: 4.766

9.  Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis.

Authors:  R S Eisenstaedt; T E Getzen
Journal:  Am J Public Health       Date:  1988-04       Impact factor: 9.308

Review 10.  Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.

Authors:  J W Hay; W M Yu; T Ashraf
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.558

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.